Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512806 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL13207905 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12711208 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL1055883 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL13058696 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12735687 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL2511997 | 1.00 | — | — | |
| Inositol SCHEMBL2422938 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL187397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4516303-A1 | COMPOSITION INCLUDING TEUPOLIOSIDE AND INOSITOL | IDI Integratori Dietetici Italiani S.r.l. (IT) | 2025-03-05 | — | — | EP | claimed |
| CN-119213079-A | Stabilized transition metal-containing plastic compositions, molding compounds or molded parts, and use of stabilizer compositions for stabilizing transition metal-containing plastics | 弗劳恩霍夫应用研究促进协会 | 2024-12-27 | — | — | CN | claimed |
| US-20240398957-A1 | ADDITIVES FOR PROTEIN FORMULATIONS TO IMPROVE THERMAL STABILITY | MERCK PATENT GMBH (DE) | 2024-12-05 | — | — | US | claimed |
| EP-4076403-A1 | GASTRO-RESISTANT MICROPARTICLES COMPRISING INOSITOL AND/OR GYMNEMA SYLVESTRE EXTRACT, PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | IDI Integratori Dietetici Italiani S.r.l. (IT) | 2022-10-26 | — | — | EP | claimed |
| EP-4034092-A1 | SCYLLO-INOSITOL AND ITS USE AS INSULIN SENSITIZER | Société des Produits Nestlé S.A. (CH) | 2022-08-03 | — | — | EP | claimed |
| US-20220211854-A1 | NITROREDUCTASE-RELEASABLE PRO-DRUGS AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA, A BODY CORPORATE (US) | 2022-07-07 | — | — | US | claimed |
| EP-4021429-A1 | SCYLLO-INOSITOL AND B-CELL MEDIATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2022-07-06 | — | — | EP | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| US-20210379186-A1 | ADDITIVES FOR PROTEIN FORMULATIONS TO IMPROVE THERMAL STABILITY | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | claimed |
| WO-2021124244-A1 | GASTRO-RESISTANT MICROPARTICLES COMPRISING INOSITOL AND/OR GYMNEMA SYLVESTRE EXTRACT, PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | IDI INTEGRATORI DIETETICI ITALIANI S.R.L. (IT) | 2021-06-24 | — | — | WO | claimed |
| WO-2001028356-A2 | FOOD SUPPLEMENT FOR INCREASING LEAN MASS AND STRENGTH | MUSCLETECH RESEARCH AND DEVELOPMENT INC. (CA) | 2001-04-26 | — | — | WO | claimed |
| JP-2001501910-A | — | — | 2001-02-13 | — | — | JP | claimed |
| EP-1021388-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 2000-07-26 | — | — | EP | claimed |
| US-5998485-A | DOSE DEPENDENT | CEDARS-SINAI MEDICAL CENTER (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998057620-B1 | INOSITOL FOR MODULATION OF IMMUNE RESPONSE | CEDARS SINAI MEDICAL CENTER (US) | 1999-04-15 | — | — | WO | claimed |
| WO-1998057620-A2 | INOSITOL FOR MODULATION OF IMMUNE RESPONSE | CEDARS-SINAI MEDICAL CENTER (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
| US-5633412-A | Syntheses of D-chiro-3-inosose and (+)-D-chiro inositol | VIRGINIA TECH INTELLECTUAL PROPERTIES (US) | 1997-05-27 | — | — | US | claimed |
| WO-1994007897-A1 | SYNTHESES OF D-CHIRO-3-INOSOSE AND (+)-D-CHIRO-INOSITOL | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1994-04-14 | — | — | WO | claimed |
| US-4096036-A | ION EXCHANGE, COMPLEXING | STANDARD BRANDS INCORPORATED (US) | 1978-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211854-A1 | NITROREDUCTASE-RELEASABLE PRO-DRUGS AND METHODS FOR USING THE SAME | AKR1B1, AKR1A1, POR | LMNA 1971/4885APP 3921/4885GBA1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.